Because E2 is known to reduce CD4+ T cell HIV-1 infection susceptibility in vitro (40, 44), we next assessed whether E2 treatment could reverse the observed increases in endometrial CD4+ T cell infection susceptibility following menopause as described in the methods. Here, CD4 is linked to HIV-1 infection.